Martin M Matzuk

US Patent:

6548738, Apr 15, 2003

Filed:

Dec 26, 2000

Appl. No.:

09/749109

Inventors:

Salih J. Wakil - Houston TX
Martin M. Matzuk - Pearland TX
Lutfi Abu-Elheiga - Houston TX

Assignee:

Research Development Foundation - Carson City NV

International Classification:

A01K 67027

US Classification:

800 18, 435325, 435455

Abstract:

The present invention discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase-2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The transgenic mice of the instant invention provide a useful animal model to identify such inhibitors and for studying the mechanisms of fat metabolism and weight control.

US Patent:

6680174, Jan 20, 2004

Filed:

Apr 1, 1999

Appl. No.:

09/283909

Inventors:

Martin M. Matzuk - Pearland TX
Julia A. Elvin - Houston TX
Pei Wang - Houston TX

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

G01N 33567

US Classification:

435 721, 435 72, 435212, 435215, 435217, 424 92, 530399, 530324, 530350

Abstract:

The present invention relates to a method of identifying an agent which alters (inhibits, enhances) activity of GDF-9. The method involves combining cells having a receptor for GDF-9 and a gene, wherein expression of the gene is regulated by binding of GDF-9 to the receptor; GDF-9; and an agent to be assessed. The combination produced is maintained under conditions appropriate for binding of GDF-9 to the receptors on the cells. The extent to which binding of GDF-9 to the receptors on the cells occurs is then determined, wherein binding of GDF-9 to the receptor to a lesser or greater extent in the presence of the agent to be assessed than in its absence, is indicative of an agent which alters GDF-9 activity.

US Patent:

6734337, May 11, 2004

Filed:

Aug 14, 2001

Appl. No.:

09/929575

Inventors:

Salih J. Wakil - Houston TX
Martin Matzuk - Pearland TX
Lutfi Abu-Elheiga - Houston TX

Assignee:

Research Development Foundation - Carson City NV

International Classification:

G01N 3300

US Classification:

800 3, 800 8, 800 18

Abstract:

The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. The instant invention provides a useful animal model to regulate malonyl-CoA production by ACC2 in the regulation of fatty acid oxidation by muscle, heart, liver and other tissues. They also identify potential inhibitors for studying the mechanisms of fat metabolism and weight control.

US Patent:

6995251, Feb 7, 2006

Filed:

Oct 28, 1999

Appl. No.:

09/830810

Inventors:

Martin M. Matzuk - Pearland TX, US
Pei Wang - Houston TX, US

Assignee:

Baylor - Houston TX

International Classification:

C07H 21/00

US Classification:

536 235, 4352523, 4353201, 435325

Abstract:

Ovary-specific proteins O1-180, O1-184 and O1-236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1-180, O1-184 or O1-236 are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1-180, O1-184 or O1-236. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures. Furthermore, assays of the proteins/mRNAs/genes of the invention can be used in diagnostic assays for detecting forms of infertility and other diseases, including germ cell tumors and polycystic ovary syndrome. The proteins of the invention may be useful targets for in vitro fertilization procedures or in enhancing the number of eggs that can be retrieved from the human donor, e. g.

US Patent:

7227013, Jun 5, 2007

Filed:

Mar 31, 1999

Appl. No.:

10/018638

Inventors:

Martin Matthew Matzuk - Pearland TX, US
Julia Andrea Elvin - Houston TX, US

Assignee:

Metamorphix, Inc. - Savage MD

International Classification:

C07H 21/04
C12N 15/63

US Classification:

536 241, 536 231, 4353201

Abstract:

Isolated GDF-9 regulatory sequences are disclosed, as well as methods of using the sequences to modulate tissue-specific expression of genes. The GDF-9 regulatory sequences include, for example, enhancer and promoter elements that naturally drive transcription of GDF-9 in specific tissues. The GDF-9 regulatory sequences can be derived from the untranscribed upstream (e. g. , first 10 kilobases) and downstream regions, and transcribed, untranslated regions of a GDF-9 gene.

US Patent:

7232678, Jun 19, 2007

Filed:

May 16, 2003

Appl. No.:

10/439741

Inventors:

Martin M. Matzuk - Pearland TX, US
Yuchen Bai - Newtown PA, US
Wei Yan - Houston TX, US

Assignee:

Wyeth - Madison NJ
Baylor College of Medicine - Houston TX

International Classification:

C12N 9/22
C12N 15/70
C12Q 1/68
C12P 21/06
C07H 21/04
A61K 38/47

US Classification:

435199, 435 6, 435325, 435 691, 4353201, 536 232, 424 9461

Abstract:

The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.

US Patent:

7335737, Feb 26, 2008

Filed:

Nov 9, 2005

Appl. No.:

11/270717

Inventors:

Martin M. Matzuk - Houston TX, US
Pei Wang - Houston TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

C07K 14/00
A61K 38/00

US Classification:

530350, 4241851

Abstract:

Ovary specific proteins O1 180, O1 184 and O1 236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1 180, O1 184 or O1 236 are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1 180, O1 184 or O1 236. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures. Furthermore, assays of the proteins/mRNAs/genes of the invention can be used in diagnostic assays for detecting forms of infertility and other diseases, including germ cell tumors and polycystic ovary syndrome. The proteins of the invention may be useful targets for in vitro fertilization procedures or in enhancing the number of eggs that can be retrieved from the human donor, e. g.

US Patent:

20020042926, Apr 11, 2002

Filed:

Apr 27, 2001

Appl. No.:

09/844864

Inventors:

Martin Matzuk - Pearland TX, US
Pei Wang - Houston TX, US

International Classification:

A01K067/027
C07H021/04
C12N009/00

US Classification:

800/018000, 536/023200, 435/183000

Abstract:

Ovary-specific proteins O1-180, O1-184 and O1-236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1-180, O1-184 or O1-236 and transgenic mice comprising disruptions of those genes are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1-180, O1-184 or O1-236 and for creating transgenic mice comprising disruptions of those genes. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures. Furthermore, assays of the proteins/mRNAs/genes of the invention can be used in diagnostic assays for detecting forms of infertility and other diseases, including germ cell tumors and polycystic ovary syndrome. The proteins of the invention may be useful targets for in vitro fertilization procedures or in enhancing the number of eggs that can be retrieved from the human donor, e.g., in enhancing the success rate.